Knowledge base · September 30, 2026 · Updated October 31, 2026 · Stefan Bensmo

FDA-Authorized Nicotine Pouches in 2026: PMTA, MGO and MRTP Explained

As of 21 October 2026, the FDA lists 43 nicotine pouch products that may lawfully be sold in the United States. A PMTA marketing authorization permits a specific product to be marketed; it is not an FDA approval or a declaration that the product is safe. Twenty of those products — specific ZYN variants — also hold separate modified-risk orders allowing one precisely worded comparative-risk claim.

The three terms that are most often confused

Which nicotine pouches are authorized?

FDA's current authorized-pouch list listed 43 products from two manufacturers: Helix Innovations LLC (12 on!/on! PLUS) and Swedish Match USA, Inc. (31 ZYN/ZYN ULTRA). On 30 October 2026 the FDA authorized 24 VELO products from Modoral Brands Inc., bringing the total to 67 from three manufacturers (FDA). Modoral is a Reynolds American subsidiary, part of BAT (Tobacco Reporter). The VELO products are VELO Mini Pouch and Mini Pouch 2 in eight flavour names, all at 4 mg, in three package types. On 31 October the list page itself had not yet been updated. FDA states that these are the only nicotine pouch products that may lawfully be sold in the United States and points to its searchable tobacco-product database as the most comprehensive legal-market list.

The count is a snapshot, not a permanent market total. FDA says it intends to update the authorized-pouch page on the day of a new authorization. For due diligence, verify the exact product name, strength and manufacturer in the marketing-order records; a similar brand name is not enough.

An application is not an authorisation. A current example: on October 1, 2026, the independent US company Skoka filed a bundled PMTA for 55 nicotine pouch products in 11 varieties and five strengths. The company says it has committed $15 million to its regulatory programme and completed three pharmacokinetic studies, and plans to launch in US retail in 2027 if the products are authorised (Nicotine Insider). Until FDA issues a marketing order, none of the 55 products is on the authorised list above.

How FDA evaluates a PMTA

The legal standard is whether marketing the specific new product is appropriate for the protection of public health. FDA evaluates risks and benefits to the population as a whole, including people who use tobacco and people who do not. Product chemistry, toxicology, manufacturing controls, use behaviour, youth risk, labelling and marketing plans can all be relevant. Each order is product-specific: one flavor, strength or format cannot inherit another variant's authorization.

The 11 ZYN ULTRA products authorized on 21 August 2026 illustrate that specificity. FDA's order announcement names every authorized flavor and strength; authorization of ZYN ULTRA Smooth 11 mg does not authorize an unlisted strength or another pouch sold under a related name.

What the ZYN modified-risk decision changed

On 30 June 2026, FDA issued modified-risk granted orders for 20 ZYN products already authorized for sale since January 2025. The separate MRTP decision allows those named 3 mg and 6 mg products to carry one specified claim comparing the risks of using ZYN instead of cigarettes. It did not convert every ZYN product into an MRTP: the later ZYN ULTRA products are not among those 20 orders.

This distinction matters in both editorial coverage and commercial compliance. “FDA-authorized for marketing” describes an MGO. “Authorized to use a modified-risk claim” is only accurate when the exact product and exact claim are covered by an MRTP order.

Environmental review is part of the file, not a category-wide approval

FDA's 2026 programmatic environmental assessment provides common scientific background for nicotine pouches and other products in the “other” category. FDA still issues product-specific environmental documentation with its decisions. The programmatic assessment therefore does not authorize a product and should not be described as a blanket environmental approval.

A practical verification workflow

1. Match the exact product. Record manufacturer, brand, flavor, nicotine strength and order number.
2. Confirm the order type. Distinguish an MGO from an MRTP order, denial, application filing or pending review.
3. Read the order conditions. Authorization can carry reporting, advertising and post-market surveillance requirements.
4. Check the current FDA record at the decision date. A press release or company statement should not replace the regulator's product record.
5. Describe status precisely. Use “authorized for marketing,” not “FDA approved,” and never extend an order to an unlisted variant.

For structured support on US regulatory research, see regulatory and marketing advisory.